Indacaterol, a novel once daily inhaled β2-adrenoreceptor agonist

Open Respiratory Medicine Journal

Volumn 3, Issue , 2009, Pages 27-30

  Roig, Jorge ^a   Hernando, Rosana ^b   Mora, Ramon ^c  

^a HOSPITAL NOSTRA SENYORA DE MERITXELL   (Andorra)

^b HOSPITAL CLÍNIC   (Spain)

^c NONE

Author keywords

Activity profile; Indacaterol; Safety; Tachyphylaxis

Indexed keywords

FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; ISOPRENALINE; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; METERED DOSE INHALER; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TACHYPHYLAXIS;

EID: 70449523718     PISSN: None     EISSN: 18743064     Source Type: Journal    
DOI: 10.2174/1874306400903010027     Document Type: Review

References (34)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-55.
2. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 143-78.
3. Claxton AJ, Cramer J, Pierce CA. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-310.
4. Sears MR, Lötvall J. Past, present and future - β2-adrenoceptor agonists in asthma management. Respir Med 2005; 99: 152-70.
5. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 2008; 155: 291-9.
6. 2- adrenoceptor Agonists an emerging therapeutic option for asthma and COPD?. Drugs 2007; 67: 503-15.
7. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545-55.
8. 2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006; 317: 762-70.
9. Currie GP. Indacaterol Novartis/SkyePharma. Cur Opin Invest 2006; 7: 457-63.
10. Naline E, Molimard M, Fairhurst R, Trifilieff A, Advenier C. Pharmacological characterization of indacaterol, a novel 24-hour b2-agonist, on the isolated human bronchus. Eur Respir J 2005; 26 (Suppl 49): 216S.
11. 2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 2007; 29: 871-8.
12. 2- agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol 2008; 101: 90-5.
13. 2 adrenoceptor agonist, on small airways in human and rat precisioncut lung slices. J Pharmacol Exp Ther 2008; 324: 270-5.
14. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008; 102: 1033-44.
15. LaForce C, Alexander M, Deckelman R, et al. Indacaterol provides sustained 24h bronchodilation on once-daily doping in asthma: a 7-day dose-ranging study. Allergy 2008: 63: 103-11.
16. 2-agonist, on isolated human bronchi. Eur Respir J 2007; 29: 575-81.
17. Naline E, Zhang Y, Qian Y, et al. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J 1994; 7: 914-20.
18. Bennet JA, Tattersfield AE. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax 1997; 52: 458-64.
19. Bennet JA, Smyth ET, Pavord ID, Wilding PJ, Tattersfield AE. Systemic effects of salbutamol and salmeterol in patients asthma. Thorax 1994; 49: 771-4.
20. Maconochie JG, Forster JK. Dose-response study with high-dose inhaled salmeterol in healthy subjects. Br J Clin Pharmacol 1992; 33: 342-5.
21. Bremmer P. Woodmarn K, Burgess C, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993; 6: 204-10.
22. Burgess C, Ayson M, Rajasingham S, Crane J, Della CG, Till MD. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. Eur J Clin Pharmacol 1998; 54: 141-7.
23. Totterman KJ, Huhti L, Sutinen E, et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur Respir J 1998; 12: 573-9.
24. Sears MR. Adverse effects of β-agonists. J Allergy Clin Immunol 2002; 110: S322-28.
25. Salpeter SR, Omiston TM, Salpeter EE. Cardiovascular effects of β2-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125: 2309-21.
26. 2agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study. Eur Respir J 2005; 26(Suppl 49), 253s.
27. Chuchalin AG, Tsoi AN, Richter K, et al. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med 2007; 101: 2065-75.
28. 2-agonist, is well tolerated in patients with asthma: a randomized, placebo-controlled 28-day safety study. Ann Allergy Asthma Immunol 2007; 99: 555-61.
29. 2-agonist, in patients with COPD: A 28- day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 2007; 20: 740-9.
30. Maesen FP, Costongs R, Smeets JJ, Brombacher PJ, Zweers PG. The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest 1991; 99: 1367-73.
31. Brookman LJ, Knowles LJ, Barbier M, Elharrar B, Fuhr R, Pascoe S. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Curr Med Res Opin 2007; 23: 3113-22.
32. Bauwens O, Ninane V, Van de Maele B, et al. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with comparison with placebo and formoterol. Curr Med Res Opin 2009; 25: 463-70.
33. Cooper N, Walker I, Knowles I. NVA237 and tiotropium bromide demonstrate similar efficacy in n anesthetized rabbit model of methacholine-induced bronchoconstriction. NVA237 demonstrates a a reduced systemic pharmacological effect on cardiovascular parameters. Proc Am Thorac Soc 2006; 3: A117.
34. Kun P, Vinkler I, Overend T, Snape S, Tansley R. Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Eur Respir J 2007; 30: 354s.